MINE (chemotherapy)

MINE in the context of chemotherapy is an acronym for one of the chemotherapy regimens used for treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma and Hodgkin lymphoma as well.

Today this regimen is often combined with monoclonal antibody rituximab. In this case the regimen is called R-MINE or MINE-R.

The [R]-MINE regimen consists of:

  1. (R)ituximab - anti-CD20 monoclonal antibody that can kill both normal CD20-expressing B cells and malignant ones;
  2. (M)esna to prevent the development of hemorrhagic cystitis which may otherwise result from ifosfamide administration;
  3. (I)fosfamide - an alkylating antineoplastic agent from oxazafosforine group;
  4. (N)ovantrone - a synthetic antracycline analogue (antraquinone) that is able to intercalate DNA and thus prevent cell division (mitosis);
  5. (E)toposide - a topoisomerase inhibitor.[1][2]

Dosing regimen

Drug Dose Mode Days
(R)ituximab 375 mg/m2 IV infusion Day 1
(M)esna 1330 mg/m2 IV infusion over 1h together with ifosfamide, plus 500 mg PO 4h after ifosfamide Days 1-3
(I)fosfamide 1330 mg/m2 IV infusion over 1h Days 1-3
(N)ovantrone 8 mg/m2 IV infusion Day 1
(E)toposide 65 mg/m2 IV infusion over 1h Days 1-3

References

  1. ↑ A phase II trial of mesna / ifosfamide, mitoxantrone and etoposide for refractory lymphomas
  2. ↑ Results of a salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP.
This article is issued from Wikipedia - version of the Wednesday, October 29, 2014. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.